Description
BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation. BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor. With an IC50 of 64nM for MRCKbeta in SCC12 cells, Ki values of 0.0136nM and 0.0233nM for MRCKalpha/beta in house determinations, respectively